Benjamin Zare (@zare_benjamin) 's Twitter Profile
Benjamin Zare

@zare_benjamin

South London Gastroenterology Specialist Registrar | Researcher @StMarksHospital | Communication Lead for GLINT @GLINT_Research | Associate PI @NIHRresearch

ID: 1534964219916976128

calendar_today09-06-2022 18:27:19

7 Tweet

40 Followers

92 Following

Charlie Lees (@charlie_lees) 's Twitter Profile Photo

Adalimumab & ustekinumab equally effective in bionaive Crohn's disease No difference across multiple endpoints after 52 weeks Both drugs highly effective: early therapy is key in CD Big missed opportunity with SEAVUE - no long-term data coming ... would love to see 2y outcomes

Adalimumab & ustekinumab equally effective in bionaive Crohn's disease

No difference across multiple endpoints after 52 weeks

Both drugs highly effective: early therapy is key in CD

Big missed opportunity with SEAVUE - no long-term data coming ... would love to see 2y outcomes
Eathar Shakweh (@eathar_s) 's Twitter Profile Photo

Excited to see the release of the new GLINT Research Group quarterly newsletter, Digest This! that went out this evening! Do check your junk mail and add us to your mailing list. Interested in signing up? Email [email protected] #gastro #research #GITwitter

Excited to see the release of the new <a href="/GLINT_Research/">GLINT Research Group</a> quarterly newsletter, Digest This! that went out this evening! Do check your junk mail and add us to your mailing list. Interested in signing up? Email glint.research@gmail.com 
#gastro #research #GITwitter
GLINT Research Group (@glint_research) 's Twitter Profile Photo

UPDATE - GLINT is launching a brand new study on endoscopic dilatation for benign oesophageal strictures - data collection will start end of Jan/early Feb’24, but sites are still being recruited so contact us to join as a UK site before we finish! #gastro #GITwitter #research

Beatriz Gros (@bealoquebea) 's Twitter Profile Photo

Risankizumab in refractory #CD patients N=53 👫51% B2 & 17% B3 behavior Perianal dis 47% Prior bowel 🔪 79% All had failed at least to 1 antiTNF (>90% to two) + VDZ + UST (and some received off label TOFA) ✅75% persisted at w52 Dont miss out our latest publication

Risankizumab in refractory #CD patients

N=53
👫51% B2 &amp; 17% B3 behavior
Perianal dis 47%
Prior bowel 🔪 79%

All had failed at least to 1 antiTNF (&gt;90% to two) + VDZ + UST (and some received off label TOFA)

✅75% persisted at w52

Dont miss out our latest publication